HU-331 represents a novel topoisomerase II inhibitor that lacks the cardiotoxicity typically associated with agents like doxorubicin.
Answers are grounded in this paper and cite their sources.
May support development of HU-331 as a less cardiotoxic topoisomerase II inhibitor; leaves open confirmation in clinical trials.
The oxidation of cannabis constituents has given rise to their corresponding quinones, which have been identified as cytotoxic agents. Out of these molecules the quinone of cannabidiol--the most abundant non-psychoactive cannabinoid in Cannabis sativa--has shown the highest cytotoxicity. This compound was named HU-331 and it exerts antiangiogenic properties, induces apoptosis to endothelial cells and inhibits topoisomerase II in nanomolar concentrations. Unlike other quinones, it is not cardiotoxic and does not induce the formation of free radicals. A comparative in vivo study in mice has shown HU-331 to be less toxic and more effective than the commonly used doxorubicin. This review summarises the properties of HU-331 and compares it with doxorubicin and other topoisomerase II inhibitors.
No takes yet. Share an insight, caveat, or question.
Peters et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: